Thursday, October 03, 2019 2:19:54 PM
Phyton BioTech resubmitted, Sept. 30th, 2019, an updated Oral Hearing Patent request for Synthesizing "PRODUCTION OF THAPSIGARGINS BY THAPSIA CELL SUSPENSION CULTURE".
Once they get this patent approved they will solve the Commercial Supply issues. Its been ongoing Since 2016.... Coincidentally around the same time $NSPX started getting quite.
https://portal.uspto.gov/pair/PublicPair -
Application Number - 15/100780
Think about it...
Started getting current in April 2019
June 17th, 2019 Updated Phase II report Published, no hype/PR.. Just Published Medically and Scientifically. https://www.mdpi.com/2072-6694/11/6/833
September 13th, 2019 They become fully reported..
October 1st, 2019 minimal RS..
October 3, 2019 Commercial Supply issue on verge of being resolved with the excepted review of the Patent submission.
During this entire time the only money the company has spent was on Getting SEC updated and OTC Current.
There are no fake/misleading/hype/crappy PR's promising anything.
$NSPX STRONGER
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM